Member Info for itsallamess

Https://www.inderes.fi/analyst-comments/faron-julkisti-odotetun-annin

"the successful offering according to the plans would clarify Faron's financial situation and offer the company the opportunity to break away from the IPF loan agreement. A successful issue would therefore also have the effect of reducing financial risk. We will update our view at the latest when the result of the auction is decided."

And her connections to big pharma are interesting.

Just view this as an opportunity to get rich.

I never thought wee could buy so cheap. Juhu is banking on the good results when phase 2 is concluded, with fast approval from the FDA and a big phama which they are in talks with paying off later this year/early next year.

I've topped up 3 times today and if I can figure out how to subscribe to the shares tomorrow, I'll take what they allow me.

Farons only getting stronger.. even if today has wiped the share price in half

Certain current shareholders of the Company and other investors have, each separately, committed to subscribe for Offer Shares in the Offering for a total of EUR 6.2 million and to pay the Subscription Price for such Offer Shares (the "Subscription Commitments"). The Subscription Commitments cover subscription of the Offer Shares for a total value of approximately EUR 6.2 million, which corresponds to approximately 6,238,724 Offer Shares, and represent approximately 20 per cent of the total number of the Offer Shares (assuming the Upsize Option is not used).

She subscribed to 46075 shares

Christine Roth. Ms. Roth currently serves as Executive Vice President, Head of the Oncology Strategic Business Unit and Member, Pharmaceuticals Executive Committee at Bayer Pharmaceuticals. Her responsibilities include global product strategy, clinical development, clinical operations, regulatory, medical affairs, and market access. Concurrently, she is is Senior Vice President, Global Oncology Therapy Area Head, at GlaxoSmithKline (GSK). Prior to these roles, she served as Vice President, US Breast Cancer Franchise Head and Vice President, Global Disease Leader, Hematology at Novartis. Her extensive experiences in the pharma space includes roles at GSK, as both the Global and US Commercialization Lead, and numerous executive and leadership roles at Bristol Myers Squibb. Ms. Roth has a Bachelor’s degree in Chemistry and has attained a Wharton Executive Education.

Well I just bought more

It's a all or nothing move from Faron

Just rung my broker X-O. They are not participating in the placing. Advice was buy in the open market or find a broker who is participating

Good question, I would subscribe for more shares.. but how?

"EUR 3.7 million will be paid by converting the Company's Capital Loans and related arrangement fees and interests into shares in the Company, gross proceeds of approximately EUR 27 million"

"Certain current shareholders of the Company and other investors have, each separately, committed to subscribe for Offer Shares in the Offering for a total of EUR 6.2 million"

My gut feeling is a big placing has already been agreed at a certain current share price..

Good news, we will have funding to take us to results for a big partner

Bad news for now the share price will be low

Good news.. buy more while it's cheap!

Placings are normally announced end if day.. and filled within a few hours..

Up to know they have been very controlled.. May be a difference if they do a public offering with no prior buys already in..

The 5000, 10000 unknown trades... buys or sells?

You would think they were sells?

Voted again

Voted

Plus you can vote again tomorrow!

It's like they know Bex works!

He is pretty confident 2024 is gonna be big for Faron

https://youtu.be/d3IrzHHS6mw?si=ghjy3JeKG454vGQ2

I'm gonna do.the same thing, drop below £ and I'm topping up

Very interesting!

"This is a once-in-a-lifetime opportunity for many Finnish investors. A banker from London said that it is rare to come across a biotech project where the finish line is already visible, but the odds are still there."